227 abstracts found.



Results filter

Studying therapy response and resistance in mouse models of human breast cancer

Year:

Session type:

Jos Jonkers1
1Netherlands Cancer Institute, Amsterdam, The Netherlands


Introduction: Epigenetics and cancer

Year:

Session type:

Peter D. Adams1
1Institute of Cancer Sciences, Glasgow, UK


Tailoring treatment in lung cancer

Year:

Session type:

Jean-Charles Soria1
1Institut Gustave Roussy, Villejuif, France


Parallel clinical trials in cells, mice and patients to define the genetic bases of response and resistance to targeted therapies in CRCs

Year:

Session type:

Alberto Bardelli1
TOUniversity of Torino-Medical School, Candiolo


The challenges for the implementation of molecular diagnostics in the clinical setting

Year:

Session type:

David Gonzalez de Castro1
1The Institute of Cancer Research, London, UK


Introduction: Transformational impact of symptom control for cancer patients

Year:

Session type:

Peter Selby1
1Cancer Research UK Centre, Leeds, UK


Overview on how symptom control and dealing with toxicity has changed over the last decade and enabled the delivery of more complex and effective treatment

Year:

Session type:

Martin Gore1
1Royal Marsden Hospital, London, UK


Cancer and bone – minimizing the clinical impact of bone complications

Year:

Session type:

Robert Coleman1
1Weston Park Hospital, Sheffield, UK


Work and cancer survivors

Year:

Session type:

Michael Feuerstein1
1Uniformed Services University, Bethesda Maryland, USA


Introduction: Colorectal cancer screening in the United Kingdom: Successes, failures and future developments

Year:

Session type:

Robert Steele1
1University of Dundee, Dundee, UK


Food, nutrition, physical activity, and cancer prevention: evidence and recommendations

Year:

Session type:

Martin Wiseman1
1WCRF International, London, UK


Chemoprevention successes and surprises

Year:

Session type:

John Baron1
1University of North Carolina, Chapel Hill, NC, USA


Polygenic risk prediction: The clinical significance

Year:

Session type:

Paul Pharoah
University of Cambridge, UK


Unexplained familial breast cancer risk – how can we find the missing genes?

Year:

Session type:

Julian Peto
London School of Hygiene and Tropical Medicine, UK


Interrogating regulatory networks to elucidate drivers of tumourigenesis, progression, and drug sensitivity

Year:

Session type:

Andrea Califano
Columbia University, New York, USA


Recent advances in breast, cervix and oral cancer early detection and prevention in low and middle income countries

Year:

Session type:

Rengaswamy Sankaranarayanan
International Agency for Research on Cancer, World Health Organization, Lyon, France


Cancer Control for India and Developing World

Year:

Session type:

Rajendra Badwe
Tata Memorial Centre, Mumbai, India


Oncology drug development in 2012 – Challenges and opportunities of stratified patient populations

Year:

Session type:

Susan Galbraith
AstraZeneca, Macclesfield, UK


Translating pre-clinical hypotheses into the clinic – a tale of two kinases

Year:

Session type:

Nigel Brooks
AstraZeneca, Macclesfield, UK


Developing novel anti-cancer therapies: Promises and challenges

Year:

Session type:

Jeff Evans
The Beatson Institute for Cancer Research, University of Glasgow & NHS Greater Glasgow and Clyde, Glasgow, UK


Delivering on the promise of personalised medicine.

Year:

Session type:

Gordon Mills
The University of Texas MD Anderson Cancer Center, USA


Targeting cancer cells and promoting the immune effectors: From models to the clinic

Year:

Session type:

Adrian Hayday
King's College London, UK


Live imaging of the earliest inflammatory response to transformed cells within tissues – studies in zebrafish

Year:

Session type:

Paul Martin
University of Bristol, UK


Peptide antigen characterization for clinical immunotherapy studies

Year:

Session type:

Hans-Georg Rammensee
University of Tübingen, Germany


PD-1 and LAG-3 in Cancer Immunotherapy

Year:

Session type:

Charles Drake
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA


Understanding cancer as a microevolutionary process

Year:

Session type:

Gerard Evans
University of Cambridge, UK


Recent insights into the tempo and mode of somatic evolution

Year:

Session type:

Carlo Maley
The University of California, San Francisco, USA


Evolutionary complexity in childhood acute lymphoblastic leukaemia

Year:

Session type:

Mel Greaves
The Institute of Cancer Research, London, UK


Evolution of cancer genomes

Year:

Session type:

Peter Campbell
Wellcome Trust Sanger Institute, Cambridge, UK


Improvements in palliative and supportive care: recent advances

Year:

Session type:

Irene Higginson
Cicely Saunders Institute, King’s College London, UK


Advances, challenges and opportunities in symptom management in older patients with cancer

Year:

Session type:

Deborah Dudgeon
Queen's University, Ontario, Canada


Recent advances in developing a national end of life care register

Year:

Session type:

Carl Johan Fürst
Karolinska Institutet, Stockholm, Sweden


Recent advances in the detection and management of psychological distress and depression in cancer and palliative care

Year:

Session type:

Mari Lloyd-Williams
University of Liverpool, UK


Lung cancer – state of the art and science

Year:

Session type:

Fergus Macbeth
Wales Cancer Trials Unit, Cardiff, UK


The application of translational science in non-small cell lung cancer (NSCLC):  Successes, failures and pitfalls 

Year:

Session type:

Frances Shepherd
University of Toronto and Princess Margaret Hospital, Ontario, Canada


Lung Stereotactic Ablative Radiotherapy (SABR): The state of the art

Year:

Session type:

Kevin Franks
St James's Institute of Oncology, Leeds, UK


Radical radiotherapy for locally advanced NSCLC – Current research and controversies

Year:

Session type:

Corinne Faivre-Finn
The Christie NHS Foundation Trust, Manchester, UK


Tumour- environment interactions

Year:

Session type:

Margaret Frame
Edinburgh Cancer Research Centre, UK


Tumour-stroma interactions in breast cancer metastasis

Year:

Session type:

Clare Isacke
The Institute of Cancer Research, London, UK


Prognostic, predictive and therapeutic potential of PDGFR-positive cancer-associated fibroblasts

Year:

Session type:

Arne Östman
Karolinska Institutet, Stockholm, Sweden


Intravital microscopy of tumour cells and their microenvironment through imaging windows

Year:

Session type:

Jacco van Rheenen
Hubrecht Institute, Utrecht, The Netherlands


Where next with genome-wide association studies?

Year:

Session type:

Bruce Ponder
Cancer Research UK Cambridge Research Institute, UK


Cancer in low and middle income countries – an increasing threat to development

Year:

Session type:

Ian Magrath
International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium


Descriptive epidemiology of cancer in developing countries and its importance to cancer control

Year:

Session type:

D. Maxwell Parkin
Clinical Trial Service Unit, University of Oxford & Cancer Registry Programme, International Network for Cancer Treatment and Research, Oxford, UK


Illuminating cancer biology with optoacoustic and thermoacoustic imaging

Year:

Session type:

Vasilis Ntziachristos1
1Helmholtz Zentrum München and Technical University Munich, Munich, Germany


Treatment-induced pain in cancer patients

Year:

Session type:

Michael Bennett1
1University of Leeds, Leeds, UK


Treatment-induced pain in cancer patients

Year:

Session type:

Patrick Dougherty1
1The University of Texas MD Anderson Cancer Center, Houston, USA


Update on targeted treatments for painful neuropathy

Year:

Session type:

Marie Fallon1
1IGMM Edinburgh Cancer Research Centre


Epidemiology and risk factors for persistent pain after breast cancer surgery

Year:

Session type:

Julie Bruce1
1University of Warwick, Coventry, UK


Clinical decision support systems

Year:

Session type:

Willie Hamilton1
1Peninsula College of Medicine and Dentistry, Exeter, UK